Vestmark Advisory Solutions Inc. Sells 11,872 Shares of Twist Bioscience Corporation $TWST

Key Points

• Vestmark Advisory Solutions Inc. reduced its holdings in Twist Bioscience Corporation by 11.5%, now owning approximately 91,056 shares valued at $3,575,000.
• Analysts have mixed opinions on Twist Bioscience, with a consensus price target of $49.40 and ratings ranging from sell to buy.
• In Q2, CEO Emily M. Leproust and CFO Adam Laponis both sold shares, indicating insider transactions that reduced their respective ownership stakes in the company.

Vestmark Advisory Solutions Inc. trimmed its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 11.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 91,056 shares of the company's stock after selling 11,872 shares during the quarter. Vestmark Advisory Solutions Inc. owned approximately 0.15% of Twist Bioscience worth $3,575,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares during the period. Deerfield Management Company L.P. Series C lifted its stake in shares of Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock worth $1,107,000 after acquiring an additional 403 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock worth $283,000 after acquiring an additional 443 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after acquiring an additional 580 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC raised its stake in Twist Bioscience by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company's stock valued at $910,000 after buying an additional 612 shares in the last quarter.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the transaction, the chief executive officer owned 645,782 shares in the company, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,089 shares of company stock worth $217,117 in the last 90 days. Company insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TWST shares. JPMorgan Chase & Co. lowered their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research report on Monday, August 4th. Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group cut their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Trading Up 0.6%

TWST stock traded up $0.1550 during trading on Thursday, hitting $26.6050. The company had a trading volume of 266,887 shares, compared to its average volume of 1,191,889. The firm has a 50-day moving average price of $33.78 and a 200-day moving average price of $36.75. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $24.28 and a 12 month high of $55.33. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -18.30 and a beta of 2.36.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.